Open AccessUse of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios
Author(s) -
Zafón Carles,
Castelo Beatriz
Publication year - 2022
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.5154
Subject(s) - lenvatinib , sorafenib , medicine , thyroid cancer , refractory (planetary science) , oncology , disease , cancer , endocrine system , cancer research , hormone , physics , astrobiology , hepatocellular carcinoma
Thyroid cancer is the most frequent endocrine tumor. In locally advanced or metastatic disease there are only two types of treatment available: radioactive iodine (RAI) while the disease is RAI‐sensitive and multikinase inhibitors, lenvatinib and sorafenib, when the disease becomes RAI‐refractory. The objective of this publication is to review the current knowledge on the use of targeted therapy and the specific practical considerations concerning lenvatinib in the treatment of patients with differentiated thyroid cancer under special circumstances.